Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 7/20 | 0.39 |
| ▸ | PPARG | P37231 | 5/20 | 0.38 |
| ▸ | PPARD | Q03181 | 5/20 | 0.38 |
| ▸ | PPARA | Q07869 | 5/20 | 0.38 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.37 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14422812 | 0.91 | ACHE (0.37) | POLQ | |
| SCHEMBL5702285 | 0.84 | PPARD (0.40) | POLQPPARGPPARDPPARACACNA1B | |
| SCHEMBL5633706 | 0.83 | POLQ (0.48) | POLQPPARGPPARDPPARA | |
| SCHEMBL5633739 | 0.83 | PPARD (0.49) | POLQPPARGPPARDPPARACACNA1B | |
| SCHEMBL5632047 | 0.83 | PPARG (0.40) | POLQPPARGPPARDPPARACACNA1B | |
| SCHEMBL14422810 | 0.82 | PPARD (0.41) | PPARGPPARDPPARA | |
| SCHEMBL5632863 | 0.82 | MRGPRX4 (0.40) | POLQPPARGPPARDPPARAMRGPRX4 | |
| SCHEMBL14422808 | 0.82 | TOP2A (0.37) | POLQ | |
| SCHEMBL14422811 | 0.82 | TOP2A (0.38) | PPARGPPARDPPARA | |
| SCHEMBL5702294 | 0.82 | CXCR2 (0.41) | POLQPPARGPPARDPPARACACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | KALYPSYS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | KALYPSYS, INC. | 2007-09-06 | — | — | US | disclosed |
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | KALYPSYS, INC. | 2007-09-06 | — | — | US | disclosed |
| WO-2004092130-A2 | N-CONTAINING HETEROAROMATIC COMPOUNDS AS MODULATORS OF PPARS AND METHODS OF TREATING METABOLIC DISORDERS | KALYPSYS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208026-A1 | N-Containing Heteroaromatic Compounds As Modulators Of Ppars And Methods Of Treating Metabolic Disorders | PPARG, PPARA, PPARD | POLQ 1293/4885PPARG 1/4885PPARD 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.